, BSc, ACGI, MBA, BSc, MBA, BEc, CA, BA, BA, LLL, JD, BSE, MA, MA, EdM, Solicitor, FCIS, FCS(PE), BSc, MBA, ACGI, MA, MBA, HonFCGI, BA, BMBCh, PhD, DM, DSc, FSB Panmure Gordon (UK) Limited Panmure Gordon (UK) Limited UBS Limited
1 1 2 3 5 8 35 37 42 51 52 53 54 56 58 59 114 *
2
3 100% 9,1804,600 540 590 7 5,110 4,6907,700 9,900 2,4802,950 AstraZeneca AB (Publ) 970 240 7 12 7 16 4,4803,010 AZD6094 8 b c-met AZD6094 c-met Fruquintinibb b Sulfatinib 32% b HMPL-523 Syk HMPL-523
4 - HMPL-004 5-2,400 AZD6094 EGFR epitinib theliatinib b PI3Kδ HMPL-689FGFRHMPL-453-29% 5.094 3.946 93% 9,990 19% 4.095 21% 2,260 1,860-6% 1,3201,250 130 190 250100 Earth s Best The Hain Celestial Group, Inc. HAINHain Celestial
5 (1) (2) Hain Celestial
6 +100% 5.4 1.382 3,280 4,480 FDA AZD6094 250 418 46% 350 6 16 1 20% 1411,472
7 GMP 42 3,000 600 13,500 8 Hain Celestial 11,400 5,1104,690 850 1,030 5,320 (1) 2,630 (2) 2,690 210 460 Nutrition Science Partners LimitedNSP 7,700 9,900 2,26080 4,380
8 100% 9,1804,600 5,020 11 4.555 3.906 1,020 960 21% 2,480 209% 280 640 620 4,480 7 150150 190 110 Hain Celestial 140 110 5% 540 59010.2 11.4
9 710BT (b) HMPL-004 Anti-TNFα 8 52 8 VEGF 1/2/3 3 2 3 AZD6094 HMPL-523 VEGFR/FGFR EGFRm+ EGFR WT c-met Syk 2 EGFR 1 EGFR + AZD9291 EGFR + EGFR + c-met c-met c-met c-met c-met BT BT BT BT BT BT BT BT BT BT HMPL-689 HMPL-453 PI3Kδ FGFR
10 2.55 7 16 13 bpoc 10 1,410 820 910 46% 418 11% HER2 trastuzumab FDA 12 13 VEGF/VEGFR EGFR bevacizumab 71
11 10 2,730 gefitinib NSCLCEGFR 16,580rituximab 500 23 TKIs 16 19 3 VEGFR EGFR AbI c-met PI3K Syk FGFR TKI 24.8% 30.5% 19.7% 74 8% 23% 17 4% pemextredcapecitabine gemcitabine20% paclitaxel docetaxel 20% DNA oxaplatintemozolomide nedaplatin 11% letrozole bicalutamideanastrozole 6% 350 250
12 (1) AZD6094 c-methmpl-523 SykHMPL-453 FGFR (2) VEGFR EGFRHMPL-689 PI3Kδ (3)HMPL- 004 TNFα IL1-β NSP b PoC PoC PoC FDA ABTPAABTPA FDA (1) (2) (3) FDA ABTPA 3 10 10 AZD6094 b PoC AZD6094HMPL-004 7,700 NSP 50/50 4.71 1.45 5.6 AZD6094 HMPL-004 5 2,4802,950 NSP 970240 NSP 7 4,480 3,010 PRCC AZD6094 500 310 2,190 Hutchison MediPharma Holdings Limited 12.2% NSP 500
13 FTE NSP AZD6094 1,430 730 1b 103 1 FGFR HMPL-453 Syk HMPL-523 PI3Kδ HMPL-689 AZD6094 HMPL-504/volitinib / savolitinibazd6094 c-met c-met HGFR c-met c-met AZD6094 c-met c-met c-metc-met+ PRCC PRCC c-met 1~20% PRCC 40~75% AZD6094 c-met PRCC >30%) AZD6094 c-met c-met PRCCAZD6094 23 c-metc-met O/E 40~92% c-metazd6094 c-met AZD6094 600 c-met AZD6094 c-met c-met 1 PRCC27 PRCC 10~15% PRCC ASCO c-met AZD6094 8 PRCC AZD6094 3 PR>30% 1 AZD6094 24 85% 3SD 8 AZD6094PRCC ORR 38% PRCCORR 13.5% foretinib PRCC 74 AZD6094 PRCC ORR FDA AZD6094c-Met PRCC 5
14 2 3 NSCLCc-Met EGFR-TKI 140 NSCLC NSCLC 30% EGFR EGFRm+EGFREGFR- TKI EGFRm+ NSCLC 20 EGFR-TKI EGFR T790Mc-Met 45-50%15-20% erlotinib EGFRm+ EGFR-TKI EGFR-TKI AZD9291 FDA NSCLC T790MEGFR-TKI AZD9291 ORR64% 30 15-20%c-MetEGFR-TKI AZD9291AZD6094 EGFR-TKI 60-70% EGFRm+ c-met FDA ORR AZD6094 3 c-met T790MEGFR-TKI NSCLC 10 4 EGFR c-met NSCLC 140 NSCLC 67% c-met 5 6 c-met 100 10%c-Met 40%c-Met 7 8 c-met AZD6094 c-met AZD6094 8AZD6094 c-met HMPL-504 volitinib 504 volitinib WHO INN volitinib INN savolitinib VEGF/VEGFR VEGF VEGFR
15 VEGF/ VEGFR TKI sorafenib sunitinib 1012 bevacizumab 71 VEGFR 253 1 HMPL- 013 VEGFR VEGFR VEGFR 1, 2, 3 VEGFR 3 1 40 b b 42 5 ORR 10.3% DCR 82.1% 9 OS 62% regoratenib 160 (n=136) ORR 4.4% DCR 51.5% 9 OS46%n=68ORR 0.0% DCR 7.4% 9OS24% b 11.9% 48.5% 71 = 2 1
16 b 420 VEGFR b PoC 18 IAS18 980 PoC (b) [1] Stivarga (b) 5 3/1 3 N = 42 3 160 3/1 N = 136 N = 68 16 9 10.3% 82.1% 66.7% 62% 4.4% 51.5% ~38% ~46% 0% 7.4% ~3% ~24% [1] = >30% = <20% =16 <20% = 9
17 2 NSCLC 80 NSCLC NSCLC NSCLC 90 NSCLC = 2 1 bevacizumab VEGFRNSCLC ramcirumab lenvatinib a 6 NSCLC 4 NSCLC NSCLC b 1 GMP VEGFR VEGFR FGFR VEGFR FGFR 3 50
18 NET octreotide/ everolimus/ sunitinib/ lanreotide/ NET (Ki67<10%) NET 15.6 / 5.9 11.0 / 4.6 11.4 / 5.5 NR / 18.0 17 0.33 0.35 0.42 0.47 p- 0.000017 <0.001 <0.001 <0.001 2% / 2% 5% / 2% 9% / 0% NR 32% 67% / 37% 73% / 51% 63% / 60% NR 100% 12,000-15,000 11 everolimus 5% ORR10% DCR 70%octreotide 6% 35-45%lanreotide FDA Ki67 10% 0% 32% 22 7 30% 100% 17 7 10 b 300 30 / bb FDA b
19 FDA EGFR EGFR EGFR EGFR EGFR EGFR gefitinib erlotinib c-met c-met EGFR EGFR 53% 66-90% EGFREGFR 10 EGFR EGFR (1) EGFR (2) EGFR EGFR EGFR c-met EGFR EGFREGFR+ EGFREGFR O/E EGFR 10-30% EGFR EGFR EGFR EGFR EGFR 614 EGFR 27-54%EGFR EGFR EGFR EGFR 18 EGFR 62% 30-90%44-52%20-48%54-66%9-62% 68% EGFR HMPL-813 EGFR EGFR EGFR EGFR
20 160 b EGFR 10% 80% b b HMPL-309 EGFREGFR EGFR EGFR 60 EGFR 24 EGFR EGFR EGFR 90 T 120 RPTD b EGFREGFR HMPL-523 HMPL-004 HMPL- 523 Syk B HMPL-004 IBD HMPL-523 HMPL-523 Syk Syk T T B B B 2017 385 Syk Rigel Syk fostamatinib Syk R406 Syk Syk Syk
21 HMPL-523Syk IC 50( )* R788 R406 Rigel/ 54 54 Syk, FLT-3, KDR, Src, Lyn, JAK rcia: 10/BID msle: 10/BID CLL: 80// 3 100BID 150QD 2ITP GS-9973 (Gilead) 55 * Syk 1NHL, CLL HMPL-523 25 51 250 Syk rcia (QD) ED min = 0.7-1/ ED 50 = 1.4-2/ 1 Syk [1] 24 19 14 9 4-1.. Naive ph2.1 HCI HMPL- 523Syk Syk HMPL-523 HMPL-523 1 3 10 30 10 MPK, QOD IP 10 MPK, BID, PO HMPL-523 (MPK, QD, PO) Enbrel R406 9 [1]MPK =QD = BID =QOD =PO = IP = Naïve = Fostamatinib Syk R406Enbrel TNF 46
22 [1] 1,800 HMPL-004 5-5-[2] 1/3 HMPL-004 HMPL-004 NSP HMPL-004 80 5- HMPL-004 HMPL-004 HMPL-004 5- b HMPL-004 NSP NATRUL-3 HMPL-004 5-420 HMPL-004 HMPL-004 NATRUL-3 NATRUL-3 5-49% b 2,400 HMPL-004 5-5- 5- NATRUL-3 5-
23 HMPL-004 2,400 5- b NATRUL-3 8 5-13% HMPL-004 2,4005-31% NATRUL-3 5-5- NATRUL-3 HMPL-004 b NATRUL-3 NSP HMPL-004 12
24 HMPL-689 Gilead Sciences idelalisib PI3Kδ B PI3Kδ Infinityduvelisib PI3Kδ Bibrutinib ibrutinib BTK B HMPL-689 PI3K duvelisib PI3Kγ(gamma) HMPL-689 Idelalisib 150 HMPL-689 HMPL-689 P450 HMPL-689 idelalisib duvelisib IC 50 HMPL-689 Idelalisib Duvelisib PI3Kδ 0.0008 (n = 3) 0.002 0.001 PI3Kγ (vs. PI3K δ) 0.114 (142X) PI3Kα (vs. PI3K δ) >1 (>1,250X) PI3Kβ (vs. PI3Kδ) HMPL-453 FGFRHMPL-453 0.087 (109X) 0.104 (52X) 0.866 (433X) 0.293 (147X) 0.002 (2X) 0.143 (143X) 0.008 (8X) HMPL- 523 HMPL-523 SykHMPL-079 Syk HMPL-689 idelalisib duvelisib Syk HMPL-523 Syk B
25 29% 5.094 3.946 19% 4.095 3.430 93% 9,9905,160 21% 2,2601,860 (i) 2607 50%(ii) 0874 50%(iii) 51% 1099 49%(iv) 600 200 65% 20% 141 1,472 34%
26 5.7 5.36 175 156 8.028.05 58 48 4.6% 5.6% 17.4% 283 250 3 5 1.41.2 2.73.3 5 (1) (2) (3) (4) (5) - 12% 1.547 1.382 23%
27 74 31 32 17 14 99.9% 14 3 13.5% 13.4% 16% 12% 1.3881.236 20 10 12% 1,380 1,240 1,700 1,600 13,500 13,000 GMP 12 78,000 40 GMP
28 3,000 1,500 3,000 500 1,500 500 5.094 29% 3,000 600 8 13,500
29 19% 3.008 2.525 147 69 69 3435 90% 28 9 80% 7% 6% 7,630 7,190 50 800 390 300 130 500,000 102 25% 5,560 H7N9 300 210 266 133 H3N2 65 36% 4,140 3,050 13% 1,830 1,630 45% 1,470 1,010 830410 6,3401,020
30 GMP 9 230,000 GMP 40 66,000 2014 1,550-51% 49% 5,020 4.8% 240 (1) 5.3 (2) 14 (3) 25% 60%
31 50% -- 500 74 51% 80% 1 5 4 70 2013 1 3 8 20 100% [2] 50% 790 147 -- 2 5 1 20 2013 280 60% [1] 294 1,700 GSP [1] 50 GSP [1] 600 1,270 2013 5202013 4 9 702013 5 1 60 [1] GSP[2]
32-9% 360 400 64% 100 60 2,000 450,000 45 18% DHA omega-3 86,100 59,400 26,700 2 22 2 800 2 2 6,600 2 140 2 58,000 4.6 300 3 9,000 400
33 6% 1,320 1,250 130 190 Hain Celestial 31 48 Hain Celestial 14% 1,150 1,020 Earth s Best 125% 230 13% 670 46% 130 29% 120 68% 130 81% 1060 Earth s Best Earth s Best 250Hain Celestial Earth s Best
34 PoC b AZD6094 PRCC c-met bhmpl-523 b PoC HMPL-689 (PI3Kδ) HMPL-453 (FGFR) HMPL-004 Earth s Best
35 1 2 3 63 5 9 4 8 1 49 6 3 7 2 48 Hutchison MediPharma (Hong Kong) Limited Sen Medicine Company Limited
36 4 5 80 Hutchison Whampoa Japan K.K. 40 65 Hutchison Whampoa Europe Investments S.à r.l. (ITU) GSMA Limited 6 7 63 67 Transport Initiatives Edinburgh Ltd. FPT Group Limited Railtrack Group plc 8 9 63 300 Biological Reviews the Journal of Physiology Europace (BA) (BMBCh) (PhD) (DM) (DSc) (FSB) 56 Tempus Energy Limited GKN Evo edrive Systems Ltd Gasrec Limited NTR plc Current OpenGrid Limited Global Crossing Ltd. North West Water International Ltd. S.G. Warburg and Co. Ltd.
37 52 56 57 14 19 23
38 91(1) 35 36 1,088,182 192,108 153,600 41,000 30,542 20,000 2,475 (i)
39 19.5.2006 (1) 768,182 (768,182) 19.5.2006 3.6.2015 1.090 25.8.2008 (3) 64,038 64,038 25.8.2008 24.8.2018 1.260 19.5.2006 (1) 76,818 (76,818) 19.5.2006 3.6.2015 1.090 11.9.2006 (2) 26,808 26,808 11.9.2006 18.5.2016 1.715 18.5.2007 (4) 40,857 40,857 18.5.2007 17.5.2017 1.535 28.6.2010 (3) 102,628 (102,628) 28.6.2010 27.6.2020 3.195 1.12.2010 (3) 177,600 (77,600) 100,000 1.12.2010 30.11.2020 4.967 24.6.2011 (3) 150,000 150,000 24.6.2011 23.6.2021 4.405 20.12.2013 (3) 896,386 (593,686) (5) 302,700 20.12.2013 19.12.2023 6.100 2,303,317 (1,025,228) (593,686) 684,403 (1) AIM 50% 25% (2) (3) 25% (4) (5) 593,686 (ii) Hutchison MediPharma Holdings Limited Hutchison MediPharma Holdings Limited
40 6.8.2008 57,000 (40,000) (17,000) 6.8.2008 5.8.2014 1.28 5.10.2009 50,000 (30,000) (20,000) 5.10.2009 4.10.2015 1.52 3.5.2010 300,000 (300,000) 3.5.2010 2.5.2016 2.12 2.8.2010 (1) 25,000 (10,000) (10,000) 5,000 2.8.2010 1.8.2016 2.24 18.4.2011 (2) 106,420 (924) (86,096) 19,400 18.4.2011 17.4.2017 2.36 17.12.2014 (3) 1,187,372 1,187,372 17.12.2014 19.12.2023 7.82 538,420 1,187,372 (80,924) (433,096) (4) 1,211,772 (1) (2) 25% (3) 25% 25% (4) 433,096(a) 39,884(b) 393,212 3% Hutchison Healthcare Holdings Limited (1) HHHL 36,666,667 69.08% Computershare Company Nominees Limited (2) CCNL 16,331,180 30.77% (3) 2,640,514 4.97% Slater Investments Limited (3) 2,263,000 4.26% (1) HHHLHHHL (2) CCNL SC167175 (3)
41 4th Floor, Hutchison House, 5 Hester Road, Battersea, London
42 AIM 35 36 (www.chi-med.com) (www.chi-med.com)
43 100% 4/4 4/4 4/4 4/4 4/4 4/4 4/4 4/4 4/4
44 AIMAIM AIM AIM 51
45 100% 3/3 3/3 3/3
46
47
48 AIM 100%
49 19,503 (1) (4) 19,503 348,888 (2) (4) 615,385 14,810 24,000 (5) 1,003,083 273,551 (2) 217,949 21,482 (5) 512,982 19,503 (3) 19,503 19,503 (1) 19,503 19,503 (3) (4) 19,503 51,488 51,488 51,488 51,488 51,488 51,488 854,915 833,334 14,810 45,482 1,748,541 (1) (2) 19,503 (3) (4) (5) 100%
50 Investor Relations 4th Floor, Hutchison House, 5 Hester Road, Battersea, London 100% info@chi-med.com
51 52 113
52 5 91,813 45,970 (72,049) (22,208) 19,764 23,762 (4,112) (3,452) (22,572) (21,295) 6 (182) 1,603 18 15,202 10,937 7 8,100 11,555 8 (1,516) (1,485) 6,584 10,070 9 (1,343) (1,050) 5,241 9,020 10 2,034 (1,978) 7,275 7,042 4,357 7,323 1,017 (1,408) 5,374 5,915 24 1,901 1,127 7,275 7,042 11(a) 0.0829 0.1407 11(b) 0.0824 0.1385 11(a) 0.1022 0.1136 11(b) 0.1016 0.1119
53 7,275 7,042 (2,819) 3,342 4,456 10,384 1,825 10,360 1,017 (1,503) 2,842 8,857 1,614 1,527 4,456 10,384
54 14 7,482 5,028 15 1,436 1,508 16 1,953 407 17 666 18 113,014 111,405 19 257 285 124,808 118,633 20 4,405 1,420 21 34,446 14,789 2,563 1,977 31 1,591 1,985 22 51,125 46,863 94,130 67,034 218,938 185,667 23 53,076 52,051 41,813 36,819 94,889 88,870 24 24,994 15,966 119,883 104,836
55 25 20,427 4,163 26 13,638 15,389 31 8,716 7,374 27 26,282 51,508 122 69,185 78,434 19 2,947 2,397 27 26,923 29,870 2,397 99,055 80,831 24,945 (11,400) 149,753 107,233 218,938 185,667
56 52,048 93,669 4,974 9,380 496 (89,989) 70,578 11,620 82,198 5,915 5,915 1,127 7,042 662 662 62 724 2,280 2,280 338 2,618 2,942 2,942 400 3,342 2,942 5,915 8,857 1,527 10,384 23(a) 3 6 (2) 7 7 332 332 25 357 (168) 168 28 (120) (243) 9,459 9,096 3,371 12,467 31(a) (577) (577) 52,051 93,675 5,016 12,079 496 (74,447) 88,870 15,966 104,836
57 52,051 93,675 5,016 12,079 496 (74,447) 88,870 15,966 104,836 5,374 5,374 1,901 7,275 (933) (933) (11) (944) (1,599) (1,599) (276) (1,875) (2,532) (2,532) (287) (2,819) (2,532) 5,374 2,842 1,614 4,456 23(a) 1,025 4,598 (2,943) 2,680 2,680 773 773 95 868 (182) 25 157 29(b) 7,526 7,526 23(b (ii)) (3) (4) (35) (42) 163 121 31(a) (1,179) (1,179) (234) (234) (234) 3,059 3,059 (2,250) (2,250) 53,076 98,273 2,661 9,543 521 (69,185) 94,889 24,994 119,883
58 29(a) (490) (4,065) 275 451 (1,466) (1,485) (908) (1,181) 15,949 11,308 13,360 5,028 (3,729) (2,500) (5,000) (12,179) 29(b) 689 (20,219) (2,500) 3,059 (2,250) (1,179) (577) 8,205 14,261 (11,277) (568) 121 2,680 7 (641) 13,123 (7,500) 15,651 46,863 30,767 (417) 445 38,946 46,863 38,946 46,863 22 12,179 22 51,125 46,863
59 1 10 22 P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands AIM 2 IFRS (a) 2(d) (b) 2(a)
60 2 (b) (c) (d)
61 2 (e) (f) 2(I)
62 2 (g) 2(f) (h) (i) (j) (k)
63 2 (l) (m) (n) (o) (p) (q)
64 2 (r) (s) (i) (ii) (t) (i)
65 2 (t) (ii) i)ii) iii) (u) (v) (w)
66 2 (x) (y) (i) (ii) (iii) (z)
67 2 1 (2) 16 38 (2) 16 41 (2) 19 (1) 27 (2) 9 (4) 10 28 (2) 10 12 28 (2) 11 (2) 14 (2) 15 (3) (1) (1) (2) (1) (2) (3) (4)
68 3 (a) (i) (ii) 28.5% 30.4%
69 3 (a) (iii) 22 27 100 565,000 509,000 (iv) 27 28 392,000 69,000 (b)
70 3 (b) 27 53,205 51,508 94,889 88,870 56.1% 58.0% (c) 4 2
71 4 (a) 1 2 3 4 980.0 5
72 4 (b) (c) 16 2(l) (d) (e) (f) 3 29(b)
73 5 (i) 66,985 16,470 (ii) 24,828 29,500 91,813 45,970 (40) 91,813 45,930 (i) 6,698.5 5,020.0 (ii) 840.0 2,220.0 1,640.0 730.0 2,482.8 980.0 4(a) EBIT/(LBIT) 10
74 5 53,832 24,828 217 12,936 91,813 91,813 EBIT/(LBIT) 1,156 (2,614) (337) 999 (796) (6,865) (7,661) 72 33 8 3 116 443 559 23,611 (8,409) 15,202 15,202 24,839 (10,990) (329) 1,002 14,522 (6,422) 8,100 87 19 106 1,410 1,516 915 3,695 2 4,612 6 4,618 68 1,145 3 7 1,223 42 1,265 136,767 52,606 1,173 7,050 197,596 21,342 218,938
75 5 EBIT 2,096 2,096 2,096 2,096 2,096 2,096
76 5 3,985 29,500 923 11,562 45,970 45,970 EBIT/(LBIT) 806 6,495 (80) (486) 6,735 (6,568) 167 9 31 12 2 54 397 451 19,702 (8,765) 10,937 10,937 20,517 (2,239) (68) (484) 17,726 (6,171) 11,555 186 186 1,299 1,485 5 2,461 2 2,468 32 2,500 16 889 3 15 923 40 963 97,271 50,272 1,768 8,312 157,623 27,113 184,736
77 5 1 (41) (40) (40) LBIT (1,141) (837) (1,978) (1,978) (1,141) (837) (1,978) (1,978) 283 648 931 931 271,000 105,000628,000 (LBIT)/EBIT (LBIT)/EBIT (796) 6,735 (6,865) (6,568) 559 451 15,202 10,937 (1,516) (1,485) 6,584 10,070 11,458,000 6,823,000 79,000120,000
78 6 559 451 (480) 1,217 20 4 (281) (69) (182) 1,603 7 607 408 37 38 48 (i) 62,464 16,823 1,180 925 (ii) 143 41 (ii) 88 185 42 36 17 810 672 4,574 4,475 13 21,297 16,517 (i) 6,246.4 4,780.0 (ii) 88,000 143,00041,000
79 8 913 922 31(a) 19 31(a) 471 471 31(a) 113 92 1,516 1,485 9 14 849 1,186 19 480 (136) 1,343 1,050 (a) 16.5% 16.5% (b)
80 9 (c) 6,584 10,070 4,464 5,115 (5,620) (4,453) 1,469 952 607 770 (1,062) (2,673) 1,161 1,029 324 310 1,343 1,050 67.8% 50.8% 20.4% 10.4%
81 10 (i) 2,096 (31) (ii) (1,947) 2,096 (1,978) (62) 2,034 (1,978) 2,515 (1,239) 2,515 (1,239) (i) (40) 2,096 9 2,096 (31) 251.5 40.0 (ii) 7 239 1 198 96 840
82 11 (a) 52,563,387 52,050,988 4,357 7,323 1,017 (1,408) 5,374 5,915 0.0829 0.1407 0.0193 (0.0271) 0.1022 0.1136 (b)
83 11 (b) 52,563,387 52,050,988 337,758 827,438 52,901,145 52,878,426 4,357 7,323 1,017 (1,408) 5,374 5,915 0.0824 0.1385 0.1016 0.1119 0.0192 12 271 280 1,432 1,381 45 43 1,748 1,704 13 15,864 12,953 1,370 1,096 3,195 2,111 868 357 21,297 16,517 9,442,0005,256,000
84 14 2,551 2,583 85 10,421 1,248 16,888 (60) (68) (2) (248) (28) (406) 29(b) 181 181 126 8 1,215 2,380 3,729 (21) (388) (409) 1,671 1,097 (2,768) 2,491 4,291 91 12,278 832 19,983 761 2,377 75 8,647 11,860 (19) (56) (2) (201) (278) 29(b) 112 112 210 380 2 588 1,180 (19) (354) (373) 952 2,682 75 8,792 12,501 1,539 1,609 16 3,486 832 7,482
85 14 2,472 2,467 78 9,059 14,076 79 79 3 299 18 478 55 4 1,211 1,230 2,500 (18) (148) (166) 2,551 2,583 85 10,421 1,248 16,888 625 2,302 60 7,745 10,732 21 73 2 255 351 115 19 13 778 925 (17) (131) (148) 761 2,377 75 8,647 11,860 1,790 206 10 1,774 1,248 5,028
86 15 1,761 1,706 (41) 55 1,720 1,761 253 208 (6) 7 37 38 284 253 1,436 1,508 16 407 407 29(b) 1,546 1,953 407 407,000407,0001,546,000
87 16 5% 5% 20% 11.0% 11.0% 11.6% 5% 5% 5% 17 6 29(b) 708 714 48 48 666 GSP
88 18 61,883 61,883 46,131 49,522 31(b) 5,000 113,014 111,405 40% (i) 50% Nutrition Science Partners Limited 43.79% (ii) NSP (i) 50% 20% (ii) NSP 50% 12.42% 12.24
89 18 (i) NSP 51,837 51,587 18,874 30,331 6,249 17,031 92,734 94,110 56,569 44,828 2,299 30 144,571 145,697 75,443 75,159 8,548 17,061 73,552 59,446 67,731 35,646 30,000 30,000 (625) (7,476) (820) (10,000) (98,260) (91,760) (44,576) (38,484) (2,902) (4,604) (98,885) (91,760) (52,052) (39,304) (12,902) (4,604) (3,858) (3,180) (19,216) (5,025) 115,380 110,203 71,906 66,476 25,646 42,457
90 18 (ii) NSP 300,842 252,465 154,703 138,160 (3,645) (3,598) (2,651) (2,612) 1,317 1,103 257 197 91 (44) 24,553 20,386 31,505 26,620 (16,811) (17,543) (3,735) (3,408) (5,103) (4,196) 20,818 16,978 26,402 22,424 (16,811) (17,543) (2,352) 3,879 (1,895) 848 18,466 20,857 24,507 23,272 (16,811) (17,543) 12,820 6,462 19,077 16,154 5,000 15,000 20,000 24,000
91 18 (iii) NSP 2013 110,203 95,808 66,476 59,358 42,457 60,000 (469) 20,818 16,978 26,402 22,424 (16,811) (17,543) (12,820) (6,462) (19,077) (16,154) (2,352) 3,879 (1,895) 848 115,380 110,203 71,906 66,476 25,646 42,457 50% 57,690 55,102 35,953 33,238 12,823 21,229 3,205 3,282 5,000 (1,901) (1,700) 55,789 53,402 39,158 36,520 17,823 21,229 244,000254,000 1,656 1,329 61,170 8,379
92 19 257 285 (2,947) (2,397) (2,690) (2,112) (2,112) (2,248) 29(b) (98) (363) 136 11 (128) (2,690) (2,112) 7,877,000 9,036,000 23,531 14,855 8,647 10,098 10,341 336 4,097 5,672 1,148 1,347 633 39,507 41,198
93 20 291 483 4,114 937 4,405 1,420 440.5 340 21 32,524 11,803 31(b) 1,922 2,986 34,446 14,789 3,252.4 1,640.0 980.0 1,670 1,554 185 42 (62) 74 1,793 1,670 1,793,0001,670,000
94 21 2,130,0003,703,000 1,136 24 959 2,106 1,608 2,130 3,703 22 32,019 20,946 (a) 6,927 25,917 (a) 12,179 51,125 46,863 8,104 12,203 (b) 40,213 32,139 247 212 2,543 1,651 18 658 51,125 46,863 (a) 7 1857 90 2.2% 2.1% (b)
95 23 (a) 1 75,000,000 75,000 52,048,448 52,048 3,000 3 52,051,448 52,051 52,051,448 52,051 1,025,228 1,025 53,076,676 53,076 1 3,000 768,182 76,818 102,628 77,600 1.535 1.090 1.090 3.195 4.967 7 1,415 141 523 601 4.40 8.35 8.35 11.55 14.58
96 23 (b) (i) 1.260 64,038 (A) 1.715 26,808 (B) 1.535 40,857 (C) 4.967 100,000 (A) 4.405 150,000 (A) 6.100 302,700 (A) 684,403
97 23 (b) (i) 3.67 2,303,317 2.22 1,459,931 6.10 896,386 1.59 (1,025,228) 1.54 (3,000) 4.97 (50,000) (D) 6.10 (593,686) 4.67 684,403 3.67 2,303,317 (A) 25% (B) (C) (D) 593,686 23(b)(ii)(D) (E) 684,403 144,000224,000 (A) 808,000206,000
98 23 (b) (i) 0.553 0.533 0.569 1.995 1.841 3.154 1.715 1.535 1.260 4.967 4.405 6.100 1.7325 1.5400 1.2600 4.6000 4.3250 6.100 (i (v) 38.8% 40.0% 35.0% 48.4% 46.6% 36.0% 4.766% 5.098% 4.700% 3.360% 3.130% 3.160% 3.4 5.3 3.9 5.7 7.1 8.0 6.25 6.25 6.25 0% 0% 0% 0% 0% 0% (i) (ii) (iii) (iv) (v)
99 23 (b) (ii) Hutchison MediPharma Holdings Limited 2.24 5,000 (A) 2.36 19,400 (B) 7.82 1,187,372 (C) 1,211,772
100 23 (b) (ii) 2.03 538,420 1.87 3,144,505 (D) 7.82 1,187,372 (E) 1.50 (80,924) 2.15 (393,212) 2.03 (120,896) (F) 1.70 (39,884) 1.79 (2,485,189) 7.71 1,211,772 2.03 538,420 (A) (B) 25% (C) 25% 25% (D) 1,187,372 23(b)(i)(D) (E) 4.55 (F) (G) 1,211,772 400,000 60,000 151,000
101 23 (b) (ii) 0.258 0.923 3.490 2.240 2.360 7.820 1.030 2.048 7.820 49% 55% 48.4% 2.007% 2.439% 1.660% 6 6 5.26 0% 0% 0%
102 24 24,994,00015,966,000 11,068,000 10,587,000 Hutchison BYS (Guangzhou) Holding Limited5,598,000 3,626,000 776,0001,753,000 7,552,000 20% (i) 12.42% (ii) 50% (iii) 49 (i) 5 4 (ii) (iii) 5 3 (i) 207 172 27,965 21,215 5,884 8,230 33,251 55,722 53,335 27,026 28,104 9 45 819 (897) (1,060) (11,456) (19,928) (4,253) (4,734) (18,346) (3,434) (3,265) (5,100) (9,600) (186) 51,598 49,182 43,535 29,391 (3,460) (6,059) 15,538
103 24 (ii) 24,828 29,500 11,531 10,157 50,202 10,272 8,286 (11,219) (2,238) 2,721 (1,215) 106 (489) (446) (21) (193) (51) 9,783 7,840 (11,219) (2,259) 2,528 (1,215) 55 (1,470) 1,352 (408) 295 71 48 124 8,313 9,192 (11,627) (1,964) 2,599 (1,167) 179 31(a) 1,179 577
104 24 (iii) 36 163 (17,521) 2,903 3,516 (136) 6,858 (3,734) (2,457) 10,274 20,000 3,982 (4,500) (4,769) 36 163 (1,255) 4,428 (984) (136) 12,363 171 8 12,969 8,227 4,525 4,609 (265) 314 (38) 52 207 171 11,449 12,969 3,503 4,525 12,363 31
105 25 18,237 1,811 31(b) 2,190 2,352 20,427 4,163 1,823.7 1,690.0 26 3,988 5,327 3,178 3,047 5,908 3,895 13,074 12,269 564 248 2,872 564 3,120 13,638 15,389
106 27 (i) 26,923 (i) (ii) 26,282 51,508 53,205 51,508 1.60% 1.80% (i) 26,923,000 (ii) (a) 26,282 51,508 26,923 53,205 51,508 (b) 53,205 48,718 2,790 53,205 51,508 28 1,247.0 4,574,780 100%87.76%
107 29 (a) 7,275 7,042 1,405 1,050 868 357 37 38 48 143 137 88 185 42 1,180 925 36 18 (559) (451) (15,202) (10,937) 1,516 1,485 165 493 (2,903) 287 80 (55) (451) (5,323) 1,412 (394) 89 (89) 324 (614) (19) (88) 2,170 980 (2,534) 160 1,320 1,157 22 (86) (490) (4,065) (3,005) (2,826) 10 2,515 (1,239) (490) (4,065)
108 29 (b) 9,597,000 51% 9,597 10,286 69 (i) 708 100 3,208 21,105 (14,827) (105) (198) (4,769) (ii) (7,526) 8,051 16 (iii) 1,546 9,597 10,286 (9,597) 689
109 29 (b) (i) GSP (ii) (iii) 1,546,000 (iv) 50,202,000 55,000 71,344,000 125,000 (v) 23,000 30 (a) 719 459 (b) 980 748 1,425 1,654 329 486 2,734 2,888
110 31 (a) 7,823 7,803 4,191 3,612 6,727 6,304 2,480 9,207 6,304 480 569 989 914 8 113 92 8 19 132 92 8 471 471 1,179 577 12 27
111 31 (b) 21 (i) 1,922 2,986 25 (i) 2,190 2,352 (i) 107 88 (i) 89 (i) 1,484 1,808 1,591 1,985 (ii) 5,000 (iii) 8,694 7,374 (i) 22 8,716 7,374 (iv) 579 579 (v) 2,550 4,800 3,129 5,379 (i) (ii) (iii) (iv) (v)
112 32 Hutchison Healthcare Holdings Limited 33 52 113 34 37,500,000 87.58% 87.76% 100% 100% 207,460,000 1,000,000 50% 50% 3,000,000 50% 50% 1 100% 100% 51% 63,570,000
113 34 40% 40% 200,000,000 50% 50% 229,000,000 Nutrition Science 20,000 43.79% 43.88% Partners Limited
114 AIM HCM P.O. Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands +1 345 949 8066 +1 345 949 8080 Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol BS99 6ZY United Kingdom +44 (0)906 999 0000 +44 (0)870 703 6114 10 22 ediths@hwl.com.hk +852 2128 1778 10 22 +852 2128 1188 +852 2128 1778 10 21 +852 2121 8200 +852 2121 8281 ir@chi-med.com +852 2121 8200 +852 2121 8281 www.chi-med.com Computershare Investor Services (Jersey) Limited Queensway House Hilgrove Street, St. Helier Jersey, Channel Islands JE1 1ES +44 (0)870 707 4040 +44 (0)870 873 5851 (a) (b)